Terms: = Uterine cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Clinical Outcome
5 results:
1. Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
Reijnen C; Vrede SW; Eijkelenboom A; Draak R; Sweegers S; Snijders MPLM; van Gestel P; Pijnenborg JMA; Bulten J; Küsters-Vandevelde HVN
Cancer Med; 2023 Jun; 12(11):12365-12376. PubMed ID: 37081760
[TBL] [Abstract] [Full Text] [Related]
2. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
3. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.
McCoy P; Mangiola S; Macintyre G; Hutchinson R; Tran B; Pope B; Georgeson P; Hong MKH; Kurganovs N; Lunke S; Clarkson MJ; Cmero M; Kerger M; Stuchbery R; Chow K; Haviv I; Ryan A; Costello AJ; Corcoran NM; Hovens CM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1167-1180. PubMed ID: 34108644
[TBL] [Abstract] [Full Text] [Related]
4. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract] [Full Text] [Related]
5. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract] [Full Text] [Related]
